{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:49:24Z","timestamp":1774723764645,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,28]]},"DOI":"10.7759\/cureus.106034","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:24:20Z","timestamp":1774722260000},"source":"Crossref","is-referenced-by-count":0,"title":["Extreme Hyperhemolysis Syndrome in a Patient With Sickle Cell Disease Successfully Managed With Eculizumab: A Case of Survival at 1.2 g\/dL Hemoglobin"],"prefix":"10.7759","author":[{"given":"Isa","family":"Cordeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Cerca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pratas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.2","article-title":"Hyperhemolysis syndrome in sickle cell disease","volume":"2","author":"Win N","year":"2009","unstructured":"Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol. 2009, 2:111-5. 10.1586\/ehm.09.2","journal-title":"Expert Rev Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.11.002","article-title":"Bystander immune cytolysis","volume":"20","author":"Petz LD","year":"2006","unstructured":"Petz LD. Bystander immune cytolysis. Transfus Med Rev. 2006, 20:110-40. 10.1016\/j.tmrv.2005.11.002","journal-title":"Transfus Med Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000499","article-title":"Alloimmunization and hyperhemolysis in sickle cell disease","volume":"2023","author":"Pirenne F","year":"2023","unstructured":"Pirenne F, Pondarr\u00e9 C. Alloimmunization and hyperhemolysis in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2023, 2023:653-9. 10.1182\/hematology.2023000499","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2348662","article-title":"What is the role of complement in bystander hemolysis? Old concept, new insights","volume":"17","author":"Evangelidis P","year":"2024","unstructured":"Evangelidis P, Evangelidis N, Vlachaki E, Gavriilaki E. What is the role of complement in bystander hemolysis? Old concept, new insights. Expert Rev Hematol. 2024, 17:107-16. 10.1080\/17474086.2024.2348662","journal-title":"Expert Rev Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17995","article-title":"How do we manage hyperhemolysis syndrome","volume":"64","author":"Adkins BD","year":"2024","unstructured":"Adkins BD, Kaylani SZ, Nero A, Ibrahim IF, Shen YM, Sarode R. How do we manage hyperhemolysis syndrome. Transfusion. 2024, 64:1822-9. 10.1111\/trf.17995","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12565","article-title":"An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME)","volume":"54","author":"Shander A","year":"2014","unstructured":"Shander A, Javidroozi M, Naqvi S, Aregbeyen O, Caylan M, Demir S, Juhl A. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion. 2014, 54:2688-95; quiz 2687. 10.1111\/trf.12565","journal-title":"Transfusion"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2016.1231988","article-title":"Expression pattern of CD55 and CD59 on red blood cells in sickle cell disease","volume":"22","author":"Al-Faris L","year":"2017","unstructured":"Al-Faris L, Al-Rukhayes M, Al-Humood S. Expression pattern of CD55 and CD59 on red blood cells in sickle cell disease. Hematology. 2017, 22:105-13. 10.1080\/10245332.2016.1231988","journal-title":"Hematology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01693.x","article-title":"Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review","volume":"48","author":"Win N","year":"2008","unstructured":"Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008, 48:1231-8. 10.1111\/j.1537-2995.2008.01693.x","journal-title":"Transfusion"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100637","article-title":"Not all red cells sickle the same: contributions of the reticulocyte to disease pathology in sickle cell anemia","volume":"40","author":"Carden MA","year":"2020","unstructured":"Carden MA, Fasano RM, Meier ER. Not all red cells sickle the same: contributions of the reticulocyte to disease pathology in sickle cell anemia. Blood Rev. 2020, 40:100637. 10.1016\/j.blre.2019.100637","journal-title":"Blood Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0251-RS","article-title":"Hyperhemolysis syndrome in patients with sickle cell disease","volume":"142","author":"Banks M","year":"2018","unstructured":"Banks M, Shikle J. Hyperhemolysis syndrome in patients with sickle cell disease. Arch Pathol Lab Med. 2018, 142:1425-7. 10.5858\/arpa.2017-0251-RS","journal-title":"Arch Pathol Lab Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13494","article-title":"How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease","volume":"170","author":"Gardner K","year":"2015","unstructured":"Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015, 170:745-56. 10.1111\/bjh.13494","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002824","article-title":"Eculizumab as a treatment for hyper-haemolytic and aplastic crisis in sickle cell disease","volume":"8","author":"Patel I","year":"2021","unstructured":"Patel I, Odak M, Douedi S, et al.. Eculizumab as a treatment for hyper-haemolytic and aplastic crisis in sickle cell disease. Eur J Case Rep Intern Med. 2021, 8:002824. 10.12890\/2021_002824","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.262006","article-title":"Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease","volume":"105","author":"Chonat S","year":"2020","unstructured":"Chonat S, Graciaa S, Shin HS, et al.. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica. 2020, 105:2887-91. 10.3324\/haematol.2020.262006","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.5_suppl_2.576S","article-title":"The impact of anemia in patients with respiratory failure","volume":"128","author":"Ouellette DR","year":"2005","unstructured":"Ouellette DR. The impact of anemia in patients with respiratory failure. Chest. 2005, 128:576S-82S. 10.1378\/chest.128.5_suppl_2.576S","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7169.1370","article-title":"Oxygen transport: 2. Tissue hypoxia","volume":"317","author":"Leach RM","year":"1998","unstructured":"Leach RM, Treacher DF. Oxygen transport: 2. Tissue hypoxia. BMJ. 1998, 317:1370-3. 10.1136\/bmj.317.7169.1370","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476450-extreme-hyperhemolysis-syndrome-in-a-patient-with-sickle-cell-disease-successfully-managed-with-eculizumab-a-case-of-survival-at-12-gdl-hemoglobin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:24:21Z","timestamp":1774722261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476450-extreme-hyperhemolysis-syndrome-in-a-patient-with-sickle-cell-disease-successfully-managed-with-eculizumab-a-case-of-survival-at-12-gdl-hemoglobin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.106034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}